Harvard Update in Clinical Cardiology 2024 (Videos + Slides)

Regular price
$75.00
Sale price
$75.00
Regular price
$0
Sold out
Unit price
Quantity must be 1 or more

Description






2024 Update in Clinical Cardiology: October 16-18, 2024


Clinical Cardiology 2024


COURSE OVERVIEW


Update in Clinical Cardiology provides comprehensive updates for state-of-the-art care and guidance to incorporate them into daily practice to optimize patient outcomes. Coverage includes:



  • Coronary Artery Disease

  • Diabetes and Obesity

  • Valvular Heart Disease

  • Cardiac Biomarkers

  • Heart Failure (reduced and preserved ejection fraction)

  • Pulmonary Hypertension

  • Cardiomyopathies

  • Dyslipidemia

  • Hypertension

  • Atrial Fibrillation

  • Supraventricular Tachycardia

  • Ventricular Arrhythmias

  • Thoracic Aortic Disease

  • Pericarditis

  • Peripheral Arterial Disease

  • Renal Artery Stenosis

  • Pulmonary Embolism and Venous Thromboembolism

  • Cardio-oncology

  • Adult Congenital Heart Disease

  • Cardiac Critical Care

  • Ischemia with Non-Obstructive Coronary Arteries (INOCA)

  • Spontaneous Coronary Artery Dissection (SCAD)

  • Heart Disease in Pregnancy

  • Sports Cardiology

  • Endocarditis


Clinical Cardiology 2024


The faculty is assembled from the best clinician-educators at Harvard Medical School and Massachusetts General Hospital and is designed to deliver the highest quality educational experience:



  • Teaching practical, effective clinical reasoning and approaches that enable you to practice state-of-the-art clinical cardiology

  • Allowing ample time for participants to interact with faculty and to pose and get answers to your specific questions, including Q&A sessions and case-based panel discussions

  • Providing the latest information in an engaging manner and clinically usable context so that you have knowledge you can “take home” and immediately apply to patient care


2024 PROGRAM HIGHLIGHTS



  • Management of obesity and diabetes for improved cardiovascular health outcomes

  • Use of GLP-1 agonists and SGLT2-inhibitors

  • Thoracic aortic disease Guideline Writing Committee chair, Dr. Eric M. Isselbacher, presents and answers your questions about the new guidelines for diagnosis and treatment

  • New clinical trials: data findings, updates, and implications for daily practice

  • Novel transcatheter and structural treatment options: important updates for the management of valvular disease

  • Optimized approaches to heart failure and cardiomyopathies, including hypertrophic cardiomyopathy and cardiac amyloidosis

  • Advances in electrical devices and mechanical support

  • Complex coronary artery disease management in the cath lab with novel diagnostic and revascularization techniques

  • Artificial intelligence (AI) and cardiovascular medicine


Clinical Cardiology 2024


Go to full site